Edition:
United States

Zealand Pharma A/S (ZELA.CO)

ZELA.CO on Copenhagen Stock Exchange

126.50DKK
4:08am EDT
Change (% chg)

kr.-0.50 (-0.39%)
Prev Close
kr.127.00
Open
kr.128.00
Day's High
kr.129.00
Day's Low
kr.125.50
Volume
107,994
Avg. Vol
108,340
52-wk High
kr.170.00
52-wk Low
kr.90.50

ZELA.CO

Chart for ZELA.CO

About

Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and... (more)

Overall

Beta: 1.13
Market Cap(Mil.): kr.3,105.13
Shares Outstanding(Mil.): 24.45
Dividend: --
Yield (%): --

Financials

  ZELA.CO Industry Sector
P/E (TTM): -- 42.14 35.24
EPS (TTM): -6.08 -- --
ROI: -26.41 -5.84 13.33
ROE: -67.66 -6.17 14.57

BRIEF-Zealand Pharma Q1 net loss widening to DKK 72.8 million

* Q1 revenue 6.5 million Danish crowns versus 6.3 million crowns year ago

May 18 2016

BRIEF-Zealand Pharma gives results of elsiglutide Phase IIb trial

* Announced on Wednesday results of Helsinn's Phase IIb trial with elsiglutide for prevention of chemotherapy-induced diarrhea in colorectal cancer patients

May 05 2016

BRIEF-Zealand Pharma Lyxumia royalty revenue for Q1 2016 up 3 pct

* Zealand reports Lyxumia royalty revenue for Q1 2016 andmsubmission by Sanofi of the fixed-ratio combination of insulin glargine (Lantus) and lixisenatide for European registration

Apr 29 2016

BRIEF-Zealand Pharma FY operating loss widens to DKK 81.3 million

* FY revenue 187.7 million Danish crowns ($27.9 million) versus 153.8 million crowns year ago

Mar 16 2016

BRIEF-Zealand: nda for the fixed-ratio combination accepted for review by the FDA

* Sanofi's NDA for the fixed-ratio combination (LixiLan) of lixisenatide and insulin glargine for Type 2 diabetes has been accepted for review by the FDA

Feb 22 2016

BRIEF-Zealand steps into phase II development in 2016 for ZP1848 for short bowel syndrome

* Zealand doses the first patients with ZP1848 for short bowel syndrome, advancing the second of its proprietary specialty medicines into phase II development in 2016

Feb 15 2016

BRIEF-Zealand Pharma Q4 lixisenatide (Lyxumia) royalty rev up 31 pct at DKK 8.1 mln

* Q4 royalty revenue from Sanofi's sales of lixisenatide (Lyxumia) outside US up at 8.1 million Danish crowns / 1.1 million euros ($1.23 million), up 15 pct over Q3, up 31 pct over Q4 2014

Feb 09 2016

BRIEF-Zealand Pharma clarifies its role in US patent litigation

* Clarifies its role in US patent litigation relating to lixisenatide between Sanofi and AstraZeneca

Feb 04 2016

BRIEF-Zealand Pharma initiates dosing of patients in Phase 2 with ZP4207

* Zealand initiates dosing of patients in Phase 2 with its stable glucagon analogue, ZP4207, for hypoglycemia in diabetes

Feb 04 2016

BRIEF-Zealand Pharma: Sanofi submits LixiLan for regulatory review in the US

* Sanofi has submitted Lixilan for regulatory review in the US, triggering a $20 million milestone payment

Dec 23 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : GlobalData
$300.00
Provider : Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.